drugset / Trial / NCT02450890

Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD

NCT02450890

Phase 3 Completed 114 enrolled Orient Pharma Co., Ltd. Durect · collab
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.

Timeline

Start
2015-06
Primary completion
2017-02
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylphenidate Small molecule 22 mg Oral
Comparator Methylphenidate Small molecule 33 mg Oral
Comparator Methylphenidate Small molecule 44 mg Oral